Imunon, Inc.
corporate_fare Company Profile
Imunon, Inc. (NASDAQ:IMNN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for IMNN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-27, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for IMNN spans S-1, 8-K, 10-Q.
Recent high-impact activity:
- Imunon Registers 20M Shares Plus 70M Warrants in Best-Efforts Follow-On
- Imunon Unveils Planned $25M Best-Efforts Offering With Up to $121.3M Milestone Warrants
- Imunon Sells ThermoDox to VoxelDox for 4.76% Equity, Up to $16.5M Milestones
- Imunon Offloads Written-Off ThermoDox Asset for Equity, Up to $16.5M in Milestones
- Imunon Exchanges $1.2M of Debt for Non-Convertible Series B Preferred Stock
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 62,366 shares in IMNN as of the October 15, 2026 settlement, a 64.0% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On October 30, 2026, 48.9% of IMNN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for IMNN, detected from its recent SEC filings · based on capital-structure filings through 2026-10-27.
Planned $25M Best-Efforts Offering · Milestone Warrants Add $121.3M Potential
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →